Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


MHLW (Japan) approves Jardiance (empagliflozin) for the treatment of chronic kidney disease (CKD) – Nippon Boehringer Ingelheim

Written by | 26 Feb 2024 | Nephrology

MHLW (Japan) approved on February 9 Nippon Boehringer Ingelheim’s SGLT2 inhibitor Jardiance (empagliflozin) for the treatment of chronic kidney disease (CKD) </p.

Jardiance has been available in Japan for the indication of type 2 diabetes and chronic heart failure. It is now newly approved for CKD, excluding patients with end-stage renal disease or those on dialysis.</p.

In the Japanese SGLT2 market, Jardiance will now be competing against AstraZeneca’s Forxiga (dapagliflozin), which already carries the same CKD indication. Mitsubishi Tanabe Pharma’s Canaglu (canagliflozin) is approved for CKD complicated with type 2 diabetes, while Astellas Pharma’s Suglat (ipragliflozin), Taisho Pharmaceutical’s Lusefi (luseogliflozin), and Kowa’s Deberza (tofogliflozin) do not have a CKD indication.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.